Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases
Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID®), a proton pump inhibitor (PPI)
Vonoprazan demonstrated superior maintenance of healing in all patients and patients with moderate-to-severe disease versus lansoprazole at Week 24
New Drug Application (NDA) submission planned for H1 2022 targeting the following indications: healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn
Phathom to host conference call today, October 18, 2021, at 8:30 am ET
Conference call on the PHALCON-EE trial results
Phathom will host a webcasted conference call today, October 18, 2021, at 8:30 am ET to discuss the PHALCON-EE study results.
To view the live webcast, visit https://investors.phathompharma.com/news-events/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.
A replay of the webcast and the slide presentation will be available after the meeting on the News & Events section of the Phathom website.
https://finance.yahoo.com/news/phathom-pharmaceuticals-announces-positive-topline-110000500.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.